NeuroStrip clears European regulatory hurdle, opening 450 million-person market
Control Bionics Limited (ASX: CBL) has been issued an EU Declaration of Conformity for its wearable surface electromyography (sEMG) device, NeuroStrip, under the EU Medical Device Regulation 2017/745 (EU MDR). Registration was confirmed in the European Database on Medical Devices (EUDAMED) on 2 October 2026, enabling NeuroStrip to be placed on the market across 27 EU member states, Iceland, Liechtenstein, Norway and Northern Ireland, a combined population of more than 450 million.
The CE marking adds a third major regulatory jurisdiction to NeuroStrip’s credentials, alongside existing registrations in the United States and Great Britain. An application to Australia’s Therapeutic Goods Administration (TGA) is also pending, indicating the company is building its regulatory footprint across multiple markets in quick succession.
UK MHRA registration, completed on 6 August 2026, came with three institutional pilot programmes already active at the time of announcement, including partnerships with British Olympics and academic sEMG researchers at the Universities of Lancaster and Sheffield.
When big ASX news breaks, our subscribers know first
What CE marking actually means for NeuroStrip
Class I classification explained
Under the EU MDR, NeuroStrip is classified as a Class I medical device, reflecting its intended purpose as a non-diagnostic sEMG measurement and biofeedback tool. Class I devices are CE marked on the basis of an EU Declaration of Conformity issued by the manufacturer, confirming the device meets the general safety and performance requirements of the EU MDR. Review by a Notified Body is not required for Class I devices.
It is worth noting that CE marking is not an approval or clearance granted by a European regulator. Rather, it is the manufacturer’s declaration that the device meets EU MDR requirements. NeuroStrip is categorised under European Medical Device Nomenclature (EMDN) code Z12062401 (electromyographic biofeedback systems), and Control Bionics holds Single Registration Number US-MF-000043550 in the European Commission’s manufacturer database.
Who can now buy NeuroStrip in Europe
CE marking enables NeuroStrip, together with the NeuroStrip app, to be supplied to a broad range of customer segments across Europe:
- Clinicians and rehabilitation providers
- Sports science organisations
- Medical researchers
The NeuroStrip app is already available via the Apple App Store, Mac App Store and Microsoft Store, meaning the commercial distribution infrastructure is in place ahead of any formal European sales push.
Regulatory rollout at a glance
The table below summarises NeuroStrip’s regulatory position as at 5 October 2026, reflecting a sequential, multi-market registration strategy across four territories.
| Market | Status | Key Detail | Date |
|---|---|---|---|
| United States | FDA establishment registration and device listing | — | August 2026 |
| Great Britain | MHRA manufacturer and device registration. UKCA marking | — | 6 August 2026 |
| European Union, EEA and Northern Ireland | EU MDR Declaration of Conformity issued. Class I. | Registered in EUDAMED | 2 October 2026 |
| Australia | TGA application submitted | ARTG inclusion pending | Submitted |
Each registration represents a distinct regulatory process completed within a compressed timeframe.
Building the global commercial foundation
Jeremy Steele, CEO and Managing Director, Control Bionics
“Europe is home to some of the world’s largest clinical rehabilitation, sports science and research communities, where customers and partners expect an established regulatory foundation before adopting a new platform. With the US, Great Britain and the EU now in place, our focus is on rapidly building our customer and partner base.”
Four markets, one platform
Control Bionics’ underlying technology platform serves four application verticals: Performance, Rehabilitation, Research & Data, and Assistive Communication. EU access expands the addressable market across all four, given Europe’s concentration of clinical rehabilitation centres, elite sports programmes, and academic research institutions.
A key adoption advantage for European clinical and research partners is that NeuroStrip does not require surgery or implantation. This non-invasive profile lowers the barriers typically associated with introducing new medical technology into clinical workflows.
The TGA application represents the next near-term regulatory catalyst. Once approved, Australia would become the fourth confirmed market for NeuroStrip.
Key points for investors to consider include:
- Three major regulatory jurisdictions now cleared (US, Great Britain, EU)
- A combined population of more than 450 million now accessible across the EU, EEA and Northern Ireland
- Commercial distribution infrastructure via major app stores already in place
- TGA approval represents the next near-term catalyst for an additional confirmed market
- NeuroStrip’s non-invasive design lowers barriers to clinical and research adoption across all registered markets
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and click the “Free Alerts” button to start receiving alerts the moment market-moving news breaks.